Coloplast A/S (CLPBY)
| Market Cap | 21.63B |
| Revenue (ttm) | 4.39B |
| Net Income (ttm) | 641.53M |
| Shares Out | n/a |
| EPS (ttm) | 2.85 |
| PE Ratio | 33.71 |
| Forward PE | 23.84 |
| Dividend | 0.19 (2.02%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 9,232 |
| Average Volume | 224,435 |
| Open | 9.67 |
| Previous Close | 9.56 |
| Day's Range | 9.58 - 9.70 |
| 52-Week Range | 9.16 - 14.14 |
| Beta | 0.53 |
| RSI | 53.14 |
| Earnings Date | Aug 19, 2025 |
About Coloplast
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the B... [Read more]
Financial Performance
In 2024, Coloplast's revenue was 27.03 billion, an increase of 10.33% compared to the previous year's 24.50 billion. Earnings were 5.05 billion, an increase of 5.62%.
Financial numbers in DKK Financial StatementsNews
Coloplast A/S (CLPBF) Q3 2025 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, 9M 2024/25
Coloplast A/S - Interim Financial Report, 9M 2024/25 2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in ...
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025
Following the changes to the Executive Leadership Team, announced on 19.08.2025*, we are pleased to share with you the updated presenters list for our Capital Markets Day on 2 September 2025. For thos...
Coloplast A/S Non-GAAP EPS of DKK 3.86, revenue of DKK 6.96B; reaffirms FY outlook
Coloplast A/S - Interim Financial Report, 9M 2024/25
2024/25 Interim financial results, 9M 2024/25 1 October 2024 - 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative imp...
Coloplast A/S - Announcement no. 05/2025 - Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team The Coloplast Board of Directors are making changes to the Executive Leadership Team (ELT) to support the successful execution of the new Colop...
Coloplast: Despite The Drawdown, Still Not A Buy
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST
Tuesday, 19 August 2025 at 11.00 - 12.00h CEST In connection with the publication of Coloplast's interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Co...
Advanced Wound Care Market to Hit $19.32 Billion by 2030 – What's Fueling the Surge? | MarketsandMarkets™.
Delray Beach, FL, July 30, 2025 (GLOBE NEWSWIRE) -- The global Advanced Wound Care Market , valued at US$12.48 billion in 2024 stood at US$13.37 billion in 2025 and is projected to advance at a resili...
Coloplast: Finally Getting Buyable
Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025
The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport) Ellehammersvej 20, 2770 Kastrup from 10.30 - 17.00 CEST (Central European Summer Time)
Coloplast A/S 2025 Q1 - Results - Earnings Call Presentation
Coloplast A/S (CLPBF) Q2 2025 Earnings Call Transcript
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf. Attachment 08052025_trading_in_shares_GL
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25
Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostom...
Coloplast A/S GAAP EPS of DKK4.05, revenue of DKK6.93B
Coloplast Seeks to Restore Investor Trust With Firing of CEO
Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns.
Coloplast A/S CEO Kristian Villumsen steps down as of today
Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO.
Coloplast A/S Revised guidance for FY 2024/25
Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024...
Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST
Tuesday, 6 May 2025 at 11.00 - 12.00am CEST In connection with the publication of Coloplast's interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host...
Coloplast: Cheaper Than In The Past, But Not Yet A Bargain
Coloplast Finance B.V. - Decisions at the Annual General Meeting
On 14 March 2025, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2023/24....